Insulin Resistance: Cause and Consequences;
Antidepressant-Induced Manic Conversion: A Developmentally-Informed
Synthesis of the Literature;
Sites of Alcohol and Volatile Anesthetic Action on Glycine
Receptors;
Role of the Orbitofrontal Cortex in Reinforcement; Processing and
Inhibitory Control: Evidence from FMRI Studies in Healthy Human
Subjects;
Common Substrates of Dysphoria in Stimulant Drug Abuse and Primary
Depression: Therapeutic Targets;
The role of cAMP response element (CRE) binding proteins in
mediating stress induced vulnerability to drug abuse;
GPCR deorphanizations;
MECHANISTIC CONNECTIONS BETWEEN GLUCOSE/LIPID DISTURBANCES AND
WEIGHT GAIN INDUCED BY ANTIPSYCHOTIC DRUGS;
Serotonin Firing Activity as a Marker for Mood Disorders: Lessons
from Knockout Mice.
Professor Peter Jenner is a specialist in preclinical aspects of
neurodegenerative diseases, notably Parkinson’s disease. He has
spent the major part of his career at King’s College London where
he was Head of Pharmacology for 14 years before returning to his
research roots and subsequently becoming Emeritus Professor of
Pharmacology. Peter has expertise in drug metabolism and
pharmacokinetics but neuropharmacology based on functional models
of neurodegenerative diseases has formed the major focus of his
work. Peter holds a BPharm, PhD and DSc degree from the University
of London. He has published well over 1000 articles with more than
700 peer reviewed papers. He is a Fellow of the Royal
Pharmaceutical Society, the British Pharmacological Society, the
Royal Society of Medicine and of King’s College London. Peter was
recently honoured with a Doctor Honoris Causa degree from Carol
Davila University of Medicine and Pharmacy, Bucharest and made an
Honorary Fellow of The British Pharmacological Society for his
contribution to research in to movement disorders.
Peter has worked closely with the pharmaceutical industry for many
years and acts as an adviser and consultant to both major pharma
and biotech companies. He has a wide knowledge of the drug
discovery and drug development process and has been involved from
molecule synthesis through to drug registration for use in man.
Peter was the Founder, Director and Chief Scientific Officer of
Proximagen, a biotech focussed on the treatment and cure of
neurodegenerative diseases that was listed on AIMs and subsequently
purchased by a US based healthcare company. He is a regular speaker
at international meetings and also takes time to speak at
Parkinson’s disease patient-carer groups across the UK.
"Invaluable reading for all biologists."- Nature "A valuable addition to any college library as current reference material for advanced undergraduates, graduate students, and professional scientists." - Choice
 |
Ask a Question About this Product More... |
|
